Concorde Asset Management Cut Lemaitre Vascular (LMAT) Holding by $606,391; Share Value Rose; Surmodics (SRDX) Valuation Rose While Trigran Investments Has Lifted Position by $684,234

May 19, 2018 - By Henry Gaston

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Logo

Douglas T. Granat increased its stake in Surmodics Inc (SRDX) by 1.97% based on its latest 2017Q4 regulatory filing with the SEC. Trigran Investments Inc bought 25,342 shares as the company’s stock rose 30.33% while stock markets declined. The hedge fund run by Douglas T. Granat held 1.31M shares of the health care company at the end of 2017Q4, valued at $36.65M, up from 1.28M at the end of the previous reported quarter. Trigran Investments Inc who had been investing in Surmodics Inc for a number of months, seems to be bullish on the $643.68M market cap company. The stock increased 1.04% or $0.5 during the last trading session, reaching $48.55. About 40,317 shares traded. Surmodics, Inc. (NASDAQ:SRDX) has risen 61.37% since May 19, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Concorde Asset Management Llc decreased its stake in Lemaitre Vascular Inc (LMAT) by 55.71% based on its latest 2017Q4 regulatory filing with the SEC. Concorde Asset Management Llc sold 19,561 shares as the company’s stock rose 13.61% while stock markets declined. The institutional investor held 15,551 shares of the health care company at the end of 2017Q4, valued at $495,000, down from 35,112 at the end of the previous reported quarter. Concorde Asset Management Llc who had been investing in Lemaitre Vascular Inc for a number of months, seems to be less bullish one the $665.12 million market cap company. The stock increased 0.12% or $0.04 during the last trading session, reaching $34.44. About 120,345 shares traded. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has risen 48.54% since May 19, 2017 and is uptrending. It has outperformed by 36.99% the S&P500.

Investors sentiment decreased to 0.91 in 2017 Q4. Its down 0.80, from 1.71 in 2017Q3. It turned negative, as 24 investors sold LMAT shares while 44 reduced holdings. 19 funds opened positions while 43 raised stakes. 13.74 million shares or 5.25% more from 13.06 million shares in 2017Q3 were reported. Public Sector Pension Board holds 0% or 9,483 shares. Aqr Mgmt Ltd Liability Com accumulated 154,318 shares. Concorde Asset Limited Liability Corp has 0.63% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Epoch reported 742,712 shares. Arizona State Retirement reported 25,581 shares. Principal Fin Gp reported 119,849 shares or 0% of all its holdings. Citigroup holds 0% or 3,162 shares. Oppenheimer Asset Management has 0.01% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Fiduciary Company has invested 0.01% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Guggenheim Capital Ltd Company holds 0% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 64,054 shares. Legal & General Grp Public Ltd invested in 0% or 27,528 shares. Invesco Limited reported 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Bahl Gaynor reported 63,825 shares stake. Manufacturers Life The invested in 11,674 shares or 0% of the stock. Menta Capital Limited Com has 21,051 shares.

Since February 26, 2018, it had 0 insider purchases, and 5 selling transactions for $5.00 million activity. Jasinski Lawrence J sold $34,000 worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) on Monday, May 7.

More important recent LeMaitre Vascular, Inc. (NASDAQ:LMAT) news were published by: Globenewswire.com which released: “LeMaitre Vascular to Present at Upcoming Investor Conferences” on May 03, 2018, also Benzinga.com published article titled: “Mid-Day Market Update: MarineMax Gains Following Q2 Results; Spectrum Brands Shares Slide”, Nasdaq.com published: “Mid-Afternoon Market Update: Dow Rises 250 Points; Chipotle Shares Spike Higher” on April 26, 2018. More interesting news about LeMaitre Vascular, Inc. (NASDAQ:LMAT) was released by: Seekingalpha.com and their article: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q1 2018 Results – Earnings Call Transcript” with publication date: April 26, 2018.

Analysts await LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report earnings on July, 26. They expect $0.42 EPS, up 82.61% or $0.19 from last year’s $0.23 per share. LMAT’s profit will be $8.11 million for 20.50 P/E if the $0.42 EPS becomes a reality. After $0.19 actual EPS reported by LeMaitre Vascular, Inc. for the previous quarter, Wall Street now forecasts 121.05% EPS growth.

Among 12 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. LeMaitre Vascular had 39 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, February 22 by Stifel Nicolaus. Stifel Nicolaus downgraded the shares of LMAT in report on Thursday, April 26 to “Hold” rating. The rating was maintained by Canaccord Genuity with “Hold” on Friday, October 27. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) has “Buy” rating given on Friday, October 27 by Stifel Nicolaus. Barrington Research upgraded LeMaitre Vascular, Inc. (NASDAQ:LMAT) on Wednesday, October 28 to “Outperform” rating. On Wednesday, January 20 the stock rating was initiated by Sidoti with “Neutral”. The firm earned “Buy” rating on Wednesday, July 29 by Benchmark. Barrington Research downgraded LeMaitre Vascular, Inc. (NASDAQ:LMAT) on Wednesday, February 22 to “Mkt Perform” rating. Roth Capital maintained it with “Buy” rating and $18 target in Monday, December 7 report. Dougherty & Company maintained LeMaitre Vascular, Inc. (NASDAQ:LMAT) on Monday, December 7 with “Buy” rating.

More notable recent Surmodics, Inc. (NASDAQ:SRDX) news were published by: Seekingalpha.com which released: “Surmodics’ (SRDX) CEO Gary Maharaj on Q2 2018 Results – Earnings Call Transcript” on May 02, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” published on May 09, 2018, Seekingalpha.com published: “FDA clears Surmodic’ low-profile catheter” on April 23, 2018. More interesting news about Surmodics, Inc. (NASDAQ:SRDX) were released by: Bizjournals.com and their article: “SurModics CFO LaFrence leaves for pharma company” published on May 16, 2018 as well as Globenewswire.com‘s news article titled: “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” with publication date: May 01, 2018.

Trigran Investments Inc, which manages about $278.36M and $445.63 million US Long portfolio, decreased its stake in Model N Inc (NYSE:MODN) by 102,755 shares to 881,839 shares, valued at $13.89M in 2017Q4, according to the filing. It also reduced its holding in Monotype Imaging Holdings In (NASDAQ:TYPE) by 203,822 shares in the quarter, leaving it with 2.08 million shares, and cut its stake in Silver Spring Networks Inc (NYSE:SSNI).

Investors sentiment decreased to 0.69 in 2017 Q4. Its down 0.25, from 0.94 in 2017Q3. It turned negative, as 11 investors sold SRDX shares while 44 reduced holdings. 12 funds opened positions while 26 raised stakes. 11.07 million shares or 0.98% less from 11.18 million shares in 2017Q3 were reported. 43,262 are owned by Ny State Teachers Retirement System. Assetmark, California-based fund reported 4 shares. Gamco Et Al holds 100,448 shares. Thrivent For Lutherans has invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Teachers Retirement System Of The State Of Kentucky holds 0% or 1,798 shares in its portfolio. Royal Fincl Bank Of Canada owns 46,660 shares. Disciplined Growth Investors Inc Mn has 0.1% invested in Surmodics, Inc. (NASDAQ:SRDX) for 178,854 shares. Rhumbline Advisers, Massachusetts-based fund reported 31,168 shares. State Common Retirement Fund reported 15,300 shares. Rice Hall James And Associate Lc has 104,386 shares for 0.11% of their portfolio. 167 are held by Pnc Services Group Inc. Gemmer Asset Mgmt Llc invested 0% in Surmodics, Inc. (NASDAQ:SRDX). Jefferies Limited Liability Corporation has invested 0% of its portfolio in Surmodics, Inc. (NASDAQ:SRDX). D E Shaw Com Inc holds 0% or 88,541 shares in its portfolio. State Board Of Administration Of Florida Retirement Sys stated it has 22,922 shares or 0% of all its holdings.

Among 5 analysts covering SurModics (NASDAQ:SRDX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. SurModics had 9 analyst reports since August 6, 2015 according to SRatingsIntel. Barrington Research downgraded Surmodics, Inc. (NASDAQ:SRDX) on Monday, November 21 to “Mkt Perform” rating. The firm has “Buy” rating by Needham given on Wednesday, May 2. Sidoti downgraded Surmodics, Inc. (NASDAQ:SRDX) on Friday, October 7 to “Neutral” rating. The firm earned “Outperform” rating on Wednesday, February 28 by Barrington Research. The company was maintained on Wednesday, May 16 by Needham. Barrington Research maintained the stock with “Outperform” rating in Thursday, August 6 report.

Since December 11, 2017, it had 0 buys, and 2 insider sales for $63,711 activity.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: